Idec

Other biotech operations that are expanding in the area include Biogen Idec, which is relocating its headquarters to Kendall Square, and Pfizer Inc., which will move into a new research building being built by MIT, also in Kendall Square.

Boston.com Top Stories 2011

Drug maker Biogen Idec Inc. is also building 495,000 square feet of new offices in Cambridge.

A Biotech Building Boom Eliot Brown 2011

Biogen Idec Inc.'s oral drug for multiple sclerosis showed success in the first of two large clinical trials, moving the company closer to gaining a foothold in an important new market.

Biogen MS Pill Shows Promise in Clinical Trial Thomas Gryta 2011

The Florida agency's resolution "was a catalyst" for Biogen Idec Inc. directors after it previously rejected declassification, recalls Naomi Aoki , a spokeswoman for the biotechnology business.

More Directors Face Yearly Votes Joann S. Lublin 2011

Mr. Martin said the restructured company will be able to focus more on its flagship multiple sclerosis treatment Tysabri which it manufactures and sells along with its U.S. joint venture partner Biogen Idec Inc.

Elan Sells EDT Unit to Alkermes Sten Stovall 2011

Separately, Biogen Idec Inc. said Tuesday its fourth-quarter earnings rose 25%, fueled by rising sales of multiple-sclerosis drugs.

Pfizer, Lilly Profits Fall as Drugs Lose Patents Peter Loftus 2012

The medicine competes with injected drugs including Biogen Idec 's Avonex and Teva Pharmaceutical Industries' Copaxone.

EU Regulator Reviews Novartis MS Pill Sten Stovall 2012

Drug maker Biogen Idec Inc. is also building 495,000 square feet of new offices in Cambridge.

A Biotech Building Boom Eliot Brown 2011

Biogen Idec Inc. said Tuesday its fourth-quarter earnings rose 25%, fueled by rising sales of multiple-sclerosis drugs, and that the company is making investments this year to fuel its research-and-development pipeline and prepare for product launches.

Biogen's Net Rises 25% as Company Invests in Pipeline Jon Kamp 2012

The label of multiple sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan Corp., has been changed to include the updated incidence of a rare brain infection.

Biogen, Elan's Tysabri Label Updated Thomas Gryta 2011